Heartware International, (FRA:HIY1) Total Stockholders Equity : €150.7 Mil (As of Jun. 2016)

View and export this data going back to . Start your Free Trial

What is Heartware International, Total Stockholders Equity?

Heartware International,'s Total Stockholders Equity for the quarter that ended in Jun. 2016 was €150.7 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Heartware International,'s Book Value per Share for the quarter that ended in Jun. 2016 was €0.26. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Heartware International,'s Debt-to-Equity for the quarter that ended in Jun. 2016 was 1.13.

Heartware International, Total Stockholders Equity Historical Data

The historical data trend for Heartware International,'s Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heartware International, Total Stockholders Equity Chart

Heartware International, Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Total Stockholders Equity

Get a 7-Day Free Trial

96.36

51.98

144.98

169.12

173.04

Heartware International, Quarterly Data
	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
Total Stockholders Equity	Get a 7-Day Free Trial															185.13	164.27	173.04	157.66	150.67

Heartware International, (FRA:HIY1) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Heartware International,'s Book Value per Share for the quarter that ended in Jun. 2016 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(150.67	-	0)	/	572.378
	=	0.26

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Heartware International,'s Debt-to-Equity for the quarter that ended in Jun. 2016 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	170.975)	/	150.67
	=	1.13

Heartware International, Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Heartware International,'s Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Heartware International, (FRA:HIY1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heartware International, Inc. (FRA:HIY1) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.heartware.com

Heartware International Inc was incorporated in Delaware on July 29, 2008 and became the successor issuer to HeartWare Limited, an Australian corporation, on November 13, 2008, as a result of the Australian Court approved redomiciliation of HeartWare Limited from Australia to Delaware. HeartWare is a medical device company engaged in developing implantable blood pumps for the treatment of advanced heart failure. The Company operates one reportable segment which includes the design, manufacture and marketing of medical devices for the treatment of advanced heart failure. The HeartWare Ventricular Assist System, which includes a left ventricular assist device, or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients with advanced heart failure. Beyond the HeartWare System, the company is also evaluating its next device, the Miniaturized Ventricular Assist Device. The MVAD is based on the same technology platform as the HeartWare System but adopts an axial flow, rather than a centrifugal flow, configuration and is being developed in multiple configurations. The MVAD designs are currently at the preclinical stage and undergoing animal studies focused on minimally invasive implantation techniques and are each approximately one-third the size of the HVAD Pump. The Company's competitors in the implantable cardiac assist space include Thoratec Corporation, Jarvik Heart, Inc., MicroMed Cardiovascular, Berlin Heart GmbH, and Sunshine Heart, Inc. HEARTWARE, HVAD, MVAD, PAL, CIRCULITE, SYNERGY and various company logos are the trademarks of the Company, in the United States, Europe, Australia and other countries.

Heartware International, (FRA:HIY1) Headlines

No Headlines